Adipokines and C-reactive protein as indicators of MetS presence in obese Greek children: The Healthy Growth Study

Emilia Vassilopoulou, Emmanouela Giannopoulou, Argiris Theodosiou, Eva Karaglani, Yannis Manios, George Moschonis

Abstract

Background: Metabolic syndrome (MetS) occurs in a proportion of overweight and obese children and increases their future risk of serious health complications, even in adolescence and young adulthood. We aimed to explore the role of certain adipokines and inflammatory markers in identifying children with MetS.

Methods: This study is a secondary analysis of data coming from the Healthy Growth Study, a cross-sectional study conducted with schoolchildren in Greece. The present study included data from a representative sample of 1376 schoolchildren (mean age: 11.19 ± 0.66 years), recruited from 77 primary schools in four large regions in Greece. Anthropometric, clinical and biochemical data were recorded. Children’s body weight status and the presence of MetS were determined and their correlation with the serum levels of leptin, adiponectin and C-reactive protein (CRP) was explored.

Results: The prevalence of the MetS was 21.7% and 3.7% in obese and overweight children, respectively. The balance of adipokines was disturbed in obesity, as the serum level of adiponectin decreased as body weight increased, while the serum level of leptin increased. The serum level of the inflammatory marker CRP increased significantly as body weight increased. Discriminant analysis showed that these factors could distinguish the children with MetS as compared to children with no MetS.

Conclusions: In the under study Mediterranean childhood population, monitoring of the levels of adipokines and CRP could identify the overweight and obese children with MetS. Appropriate individualized dietary and lifestyle interventions can be applied in these children to prevent health complications associated with MetS.

1. Background

Childhood obesity is a major health issue, increasing in global prevalence and with detrimental consequences [1,2], among which is metabolic syndrome (MetS). To date, there is no clear consensus regarding the definition of MetS, as well as the utility of its diagnosis in paediatric populations, due to the fact that its construct is challenging to define and its implications for clinical care are still unclear. Nevertheless, the term of MetS refers to clustering of the syndrome’s cardiometabolic risk factors [3]. Clinical features of MetS in childhood include obesity, dyslipidemia, hypertension and type 2 diabetes mellitus (DM) [4,5] and it has a serious impact on morbidity and mortality [6-8].

The pathophysiology of MetS is complex and is associated with various hormonal changes, including impaired regulation of adipokines and inflammatory markers [4,9]. Adipokines such as leptin and adiponectin are thought to be a link between obesity and other disturbances related to MetS [4]. Specifically in adults, adiponectin plays a protective role against insulin resistance (IR) and cardiovascular disease (CVD)
[10], and low levels are observed in various conditions associated with MetS, including hypertension, type 2 DM and IR [4]. Leptin, in contrast, has pro-inflammatory effects, and high levels of leptin are associated with the development of IR and CVD [4,11]. Hypoadiponectinemia and hyperleptinemia are observed in obese individuals, both adults and children [11–14], and the leptin/adiponectin (L/A) ratio has been proposed as a sensitive marker of MetS in children and adolescents [12,13,15,16]. In addition to the abnormal levels of adipokines, inflammation is also exacerbated in individuals with MetS [17]. More specifically increased levels of inflammatory markers, including C-reactive protein (CRP) [18], are detected in both obese adults [19] and children [19–21] with MetS. Recent data propose the use of impaired inflammatory (CRP) and insulin-adipogenic indices for stratifying senescent populations with MetS [22,23].

A significant body of research has been focused on the interrelations between adipokines, inflammation and MetS in obese children, but no relevant information is available for Mediterranean populations. The aim of this study, was to explore these associations and their implications for the identification of MetS in children, for the first time in the Mediterranean area.

2. Methods

2.1. Sampling and participants

The Healthy Growth Study (HGS) was a large-scale cross-sectional epidemiological study initiated in May 2007 and completed in June 2009. Approval to conduct the study was granted by the Greek Ministry of National Education and the Ethical Committee of Harokopio University of Athens (16/19.12.2006). The study population was representative of the 9–13 year-old school children living in the four counties under study, which are scattered throughout Greek territory, covering the northern (i.e., Thessaloniki), central (i.e., Attica), western (i.e., Aitolokarnania), and southern (i.e., Iraklio-Crete) parts of Greece (indicating potential representativeness at a national level). The sampling of schools participating in the HGS was random, multistage, and stratified by parents’ educational level and total population of students attending schools within municipalities of these counties. A detailed letter explaining the aims of the study and a consent form for conducting full measurements was provided to all parents or guardians (“parents” hereinafter) with a child in these schools. Parents who responded positively were asked to sign the consent form and provide their contact details. Data from children and their parents were collected by face-to-face interviews and clinical assessments conducted at school sites. Of the 4145 children who were eligible to participate, 2656 were enrolled in the study (64.1% response) after the parents signed consent on behalf of children [20] with a child in these schools. Parents who responded positively regarding compliance with fasting. Part of the data on the variables which determine the existence of MetS, were used for the analyses.

2.2. Anthropometric data

Schoolchildren participating in the study underwent a physical examination by two trained members of the research team. The protocol and equipment used were the same in all schools. Weight was measured to the nearest 10 g using a digital scale (Seca Alpha, model 770;Seca, Hamburg, Germany). Children were weighed without shoes and wearing the minimum clothing possible. Height was measured to the nearest 0.1 cm using a commercial stadiometer (Leicester Height Measure; Invicta Plastics, Oadby, UK) with each child standing barefoot, keeping shoulders in a relaxed position, arms hanging freely and head in the Frankfort horizontal plane [24]. Weight and height were converted to body mass index (BMI) using Quetelet’s equation (weight (kg)/height2 (m²)). Using the International Obesity Task Force (IOTF) cut-off points [25–27], students were categorized as “underweight”, “normal weight”, “overweight” or “obese”. Waist circumference (WC) was measured to the nearest 0.1 cm with the use of a non-elastic tape (Hoechstmass, Germany). Each student was advised to stand, at the end of a gentle expiration and the measuring tape was placed around the trunk, at the level of umbilicus midway, between the lower rib margin and the iliac crest [28]. For the classification of central obesity, waist circumference percentiles were used (>90th percentile) [29]. In addition, a well-trained an experienced pediatrician in each prefecture determined the pubertal stage (Tanner stage) of each subject, after a thorough visual inspection of breast development in girls and genital development in boys [30]. Finally, each girl was asked by the paediatrician about her menstruation status and age of menarche. Details of the procedure could be found elsewhere [28].

2.3. Clinical indices

Using a valid automatic Omron M6 Blood Pressure Monitor (Omron Healthcare Europe BV, Hoofddorp, The Netherlands) [31], arterial blood pressure (BP) was recorded twice, with a 2-minute interval, in the right arm, with the participant seated, and after a 5-minute rest. Prior to measurement, mid-upper arm circumference was assessed and different cuff sizes were used. In case of a difference of over 10 mmHg between the first two measurements, an additional third measurement was taken. The average values of the two measurements of systolic (SBP) and diastolic BP (DBP) of each participant were recorded and used in analysis [28].

2.4. Biochemical indices

Participating schoolchildren visited the laboratory between 08.30 and 10.30 in the morning and their blood samples were obtained after an overnight fast (12 h). The previous day, reminders were given both to parents and children regarding compliance with fasting. Part of the blood of each sample was collected in test tubes with no added anticoagulant, where it was allowed to clot for approximately 2 h, in order to achieve serum separation. Clotted blood was centrifuged at 3000 rpm for 15 min and the collected serum was divided into aliquots and stored at –80 °C, as described in depth elsewhere [32–34].

2.4.1. Lipidemic profile

Total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG) were determined twice, using commercially available enzymatic colorimetric assays (Roche Diagnostics SA, Vassilia, Switzerland) on an automated analyzer (Roche/Hitachi Modular). For the calculation of low-density lipoprotein cholesterol (LDL-C), the Friedewald equation was used [35]. The LDL-C/HDL-C and the TC/HDL-C ratios were estimated, as described elsewhere [32]. Dyslipidemias were defined using the National Cholesterol Education Program (NCEP) cut-off points for blood lipids [36].

2.4.2. Glycemic profile

Plasma glucose was determined with a commercially available enzymatic colorimetric assay (Roche Diagnostics SA, Vassilia, Swiss), and serum insulin was determined by a Chemiluminescence immunoassay (Kyowa Medex Ltd, Minami-Ishiki, Japan, for Siemens Diagnostics USA) [33].

2.4.3. Adipokine profile

Serum leptin level was measured by human leptin ELISA, Clinical Range kit (BioVendor Research and Diagnostic products, Karasek, Czech Republic) and was reported in ng/mL. Adiponectin was measured by a Human Adiponectin/Acrp30 DuoSet ELISA kit (R&D Systems, Minneapolis, MN, USA) [34] and reported in μg/mL.

2.4.4. CRP profile

As marker of inflammation, CRP was measured by human CRP ELISA
kit (R&D Systems, Minneapolis, MN, USA) and was reported in nmol/L [31].

2.5. Determination of MetS

For the purposes of the study, the International Diabetes Federation (IDF) criteria for MetS for children aged 10–16 years were used, which include the presence of central obesity plus the presence of at least two of the following components: raised triglyceride level, low HDL-cholesterol level, high BP and/or raised plasma glucose level [37].

2.6. Statistical analysis

Prior to analysis the assumption of normal distribution for the examined variables was tested. Given that Kolmogorov-Smirnov test was statistically significant for adipokines and CRP, a log-transformation was used to better approximate the normal distribution. Analysis of variance (ANOVA) was performed to explore possible differences between children of the three weight categories across all depended variables. Chi-square test of independence was used for the examination of possible association between weight category and MetS. Discriminant function analysis was conducted to investigate whether the levels of adipokine and CRP could correctly assign children in MetS and no MetS groups. For this analysis, children of underweight or normal weight who demonstrated one or two of the IDF criteria (N = 610) were excluded. All analyses were performed with SPSS Statistics 19 (SPSS Inc., Chicago, IL).

3. Results

3.1. Study population characteristics

Among the 1376 study participants, 685 were boys (49.8 %) and 691 were girls (50.2 %), with a mean age of 11.19 ± 0.66 years. Most of the children lived in an urban area (64.8 %), and the rest in a semi-urban (14.8 %) or rural (20.3 %) area. Table 1 shows the anthropomorphic characteristics of the children in the study. Regarding body weight status, 819 children (59.5 %) were normal weight or underweight, 405 children (29.4 %) were overweight and 152 children (11 %) were obese (Table 1).

3.2. Presence of MetS

According to the IDF criteria for the definition of the MetS in children and adolescents [37], only 3.5 % (48 of 1376) children demonstrated central obesity and fulfilled the criteria for MetS: 30 had a low level of HDL (62.5 %), and 13 had a raised level of triglycerides (27 %), 18 raised plasma glucose (37.5 %) and 42 had high BP (87.5 %). Table 2 shows the characteristics of the children with MetS. MetS in the study children was significantly associated with obesity ($\chi^2 (1, N = 1376) = 179.57, p < .001$, Cramer’s V = 0.361). Specifically, MetS was observed in 21.7 % of the obese children, in contrast to only 3.7 % of the overweight children, and there was no case of MetS among the normal weight and underweight children (Fig. 1).

### Table 1

Anthropomorphic characteristics of the sample of primary schoolchildren in the Healthy Growth Study.

|          | Boys (n = 685) | Girls (n = 691) | Total (n = 1376) |
|----------|---------------|----------------|-----------------|
|          | M     | SD   | M     | SD   | M     | SD   |
| Age (years) | 11.20 | 0.66 | 11.18 | 0.66 | 11.19 | 0.66 |
| Weight group |      |      |      |      |      |      |
| Underweight/Normal | 393 (57.4 %) | 426 (61.6 %) | 819 (59.4 %) |
| Overweight     | 208 (30.3 %) | 197 (28.5 %) | 405 (29.4 %) |
| Obese          | 84 (12.3 %)  | 68 (9.8 %)   | 152 (11 %)     |

3.3. Weight and adipokine levels

Possible differences to the log transformation of the serum levels of leptin, adiponectin and L/A ratio were explored among children from the three different weight categories (underweight/normal weight, overweight and obese). Significant differences were found between the three groups in all the depended variables ($p < .001$) (Table 3). The highest value of the levels of adiponectin were noticed in underweight/normal weight children (80 ± 20) and lower values in overweight (74 ± 20) and obese children (68 ± 19). Conversely, regarding the levels of leptin, the highest value was noticed in the obese category (1.18 ± 19), the lowest in the underweight/normal weight category (0.63 ± .35) whereas the overweight category demonstrated a mean value between the other two categories (1.08 ± .26). Consequently regarding the L/A ratio, underweight/normal category demonstrated the lowest value (.82 ± .54) the overweight category demonstrated a higher value than this (1.54 ± .56) and the obese category the highest (2.20 ± .78). Post hoc tests revealed that the three groups differed in all the aforementioned depended variables at least at the 0.05 level (Table 3).

3.4. Weight and CRP level

The serum levels of CRP were considerably higher in children of greater body weight. Specifically, the lowest value was noticed in underweight/normal weight children (2.54 ± .57), the highest in obese children (3.28 ± .38), while the overweight children were placed between these two groups (2.90 ± .53) (Table 3). All groups differed significantly at the 0.001 level.

3.5. Prediction of MetS

Discriminant analysis was conducted, excluding 610 children of low or normal weight, but with one or two of the IDF criteria. These children were excluded in order to examine if adipokines levels could sufficiently recognize children with MetS and undoubtedly healthy children in other words without any of the IDF criteria for MetS. As shown in Table 4, discriminant analysis revealed that the level of adipokines and CRP could distinguish the children of the two categories (discriminant function Wilks’ Lambda = .880, $\chi^2(3, 890) = 77.80, p < .001$). The leptin and CRP levels were the main contributors to this discrimination (Table 4a). The predictive accuracy of the model was good, with 96.1 % of the cross validated group cases being correctly classified (Table 4b).

4. Discussion

The present study managed to identify sufficiently well between 10–12-year-old children with and without MetS, based on the serum levels of selected adipokines (leptin and adiponectin) and the inflammatory index CRP.

In line with previous research, MetS was observed exclusively in obese and overweight children, although some of the normal and underweight children presented one or two of the IDF criteria. In a systematic review of 85 studies, the median prevalence of MetS in children was 3.3 %, ranging from 0-1% in non-obese and non-overweight populations, while in overweight children the prevalence was 11.9 %, and in obese children 29.2 % [38]. In our sample of Greek children, the corresponding rates in overweight and obese children were 3.7 % and 21.71 %.

In view of the fact that MetS has been reported to track from childhood to adulthood, where it has been associated with a higher likelihood of type 2 Diabetes and cardiovascular disease [6,7], the findings of the present study give rise to concern. As the definitions and criteria used for MetS in children and young people vary [8], we proceeded with investigation of the possible relationship with serum levels of adipokines and CRP.

We show herein that the mean level of leptin and the L/A ratio were significantly higher in overweight and obese children than in their
under- and normal weight peers, and the level of adiponectin declined significantly as body weight increased. Current documentation [12] highlights the importance of adipokine levels as a diagnostic marker for MetS in young, especially as hyperleptinemia and hypoadiponectinemia have been correlated with an increased risk of indications of metabolic imbalance, including IR and cardiometabolic dysfunction in overweight and obese children [12]. In addition, decreased levels of adiponectin are reported to enhance the inflammatory process in adipose tissue [39].

In an analogous way, the level of CRP levels, which is an established inflammatory marker, showed a significant rise with increase in body weight, in line with previous studies [18–20]. For this reason, regular monitoring of CRP is recommended for overweight individuals, as it could assist identifying those at increased cardiovascular risk [40].

Taking into consideration the varying definitions for MetS in childhood, the use of a range of markers, such as body weight and serum levels of leptin, adiponectin and CRP, can facilitate the diagnostic process. Not all obese or overweight children are at high risk of MetS, so it is important to use markers early to distinguish those at greater risk. We

Table 2
Study group’s characteristics related to weight categories and metabolic syndrome.

|                     | Normal/Underweight (n = 819) | Overweight (n = 405) | Obese (n = 152) | Total (n = 1376) |
|---------------------|------------------------------|----------------------|-----------------|------------------|
| Percentage (%)       |                               |                      |                 |                  |
| Central obesity presence (cases, %) |                              |                      |                 |                  |
| HDL normal (cases, %) |                              |                      |                 |                  |
| HDL < 40 mg/dl (cases, %)     |                              |                      |                 |                  |
| TG normal (cases, %)        |                              |                      |                 |                  |
| TG ≥ 150 mg/dl (cases, %)    |                              |                      |                 |                  |
| BP elevated (cases, %)       |                              |                      |                 |                  |

Table 3
Descriptive statistics and differences between the three weight categories in the log transformation of the serum levels of leptin, adiponectin, CRP and L/A ratio (n = 1376).

Table 4
Greek 5th and 6th grade primary schoolchildren. (a) Discriminant analysis of children with, and those without* metabolic syndrome, according to serum level of leptin, adiponectin and C-reactive protein (CRP), and (b) classification results.

Note: 96.1 % of the original group cases were correctly classified.
propose monitoring the levels of leptin, adiponectin and CRP levels in overweight and obese children in order to identify those with MetS. For these children appropriate individualized lifestyle and dietary strategies can be developed for weight management, as a preventive measure.

5. Strengths and limitations

The Healthy Growth Study was a large-scale epidemiological study, in which a representative sample of children from four main regions of Greece was recruited. The cross-sectional design of the study is an important limitation as the data cannot provide a casual pathway on the observed associations. Moreover, the relatively small number of the MetS group, in comparison to the normal weight group of children, can be considered as an additional limitation.

6. Conclusions

Based on the findings of this study, the researchers propose future focused research on identifying the cut-off levels of adipokines and CRP, to be used as potential markers for distinguishing between overweight and obese children with MetS and those without MetS. The complex nature of obesity and its profound effects on the overall health status prompts the use of a variety of different markers for optimum risk assessment and application of individualized therapeutic intervention. MetS is interrelated with serious health complications, and its diagnosis should lead to therapeutic dietary and lifestyle strategies, individualized according to personal clinical history, and food and lifestyle preferences.

Source of funding

This study was co-financed by the European Union (European Social Fund e ESF) and Greek national funds through the Operational Program “Education and Lifelong Learning” of the National Strategic Reference Framework (NSRF) - Research Funding Program: Heraclitus II. Investing in knowledge society through the European Social Fund. The funders had no involvement in any decision made regarding the study (design, data collection, interpretation, writing of the paper or manuscript submission).

Declaration of Competing Interest

The authors declare no conflict of interest.

Acknowledgements

The authors would like to thank the “Healthy Growth Study” group for the valuable contribution to the completion of the study.

References

[1] L. Abcar-Gomez, et al., Worldwide trends in body-mass index, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults, Lancet (390) (2017) 2627–2642.

[2] M. Blüher, Obesity: global epidemiology and pathogenesis, Nat. Rev. Endocrinol. 15 (May (5)) (2019) 288–298.

[3] S.N. Magge, E. Goodman, S.C. Armstrong, COMMITTEE ON NUTRITION, SECTION ON ENDOCRINOLOGY, SECTION ON OBESITY, The metabolic syndrome in children and adolescents: shifting the focus to cardiometabolic risk factor clustering, Pediatrics 140 (August (2)) (2017), e20171603.

[4] R. Kumar, S. Kumar, R. Kant, An update on metabolic syndrome: metabolic risk markers and adipokines in the development of metabolic syndrome, Diabetes Metab. Syndr. Clin. Res. Rev. 13 (July (4)) (2019) 2409–2417.

[5] D. Al-Hamad, V. Raman, Metabolic syndrome in children and adolescents, Transl. Pediatr. 6 (4) (2017) 397–407.

[6] J. Morrison, L. Friedman, C. Gray-McGuire, Metabolic syndrome in childhood predicts adult cardiovascular disease 25 years later: the princeton lipid research clinics follow-up study, Pediatrics 120 (August (2)) (2007) 340–345.

[7] J. Morrison, L. Friedman, P. Wang, C. Glaueck, Metabolic syndrome in childhood predicts adult metabolic syndrome and type 2 diabetes mellitus 25 to 30 years later, J. Pediatr. 152 (2) (2008) 201–206.

[8] S. Mottillo, K.B. Filion, J. Genest, L. Joseph, L. Pilotte, P. Poirier, et al., The metabolic syndrome and cardiovascular risk, J. Am. Coll. Cardiol. 56 (September 14) (2010) 1113–1122.

[9] K. Zorena, O. Jachimowicz-Duda, D. Słętak, M. Robakowska, M. Mrugacz, Adipokines and Obesity. Potential Link to Metabolic Disorders and Chronic Complications, LMFS 21 (May (10)) (2020) 3570.

[10] Y. Matsuura, T. Fanahashi, S. Kihara, I. Shimomura, Adiponectin and metabolic syndrome, ATVB 24 (January (1)) (2004) 29–33.

[11] M. Fasshauer, M. Blüher, Adipokines in health and disease, Trends Pharmacol. Sci. 37 (5) (May (7)) (2016) 463–470.

[12] C. Frithiof-Bjöse, M.A.V. Lund, U. Lausten-Thomsen, P.L. Hedley, O. Pedersen, M. Christiansen, et al., Leptin, adiponectin, and their ratio as markers of insulin resistance and cardiometabolic risk in childhood obesity, Pediatr. Diabetes 21 (March (2)) (2020) 194–202.

[13] G. Li, L. Xu, Y. Zhao, L. Li, J. Pu, Q. Zhang, et al., Leptin-adenosin imbalance as a marker of metabolic syndrome among Chinese children and adolescents: the BCAMS study, Chen Y-C, editor, PLoS One 12 (October (10)) (2017), e0186222.

[14] P. López-Jaramillo, D. Gómez-Arbeláez, J. López-López, C. López Lopes, J. Martínez-Ortega, A. Gómez-Rodríguez, et al., The role of leptin/adenosin ratio in metabolic syndrome and diabetes, Horm. Mol. Biol. Clin. Investig. 18 (January (1)) (2014).

[15] A. Nappo, E.M. González-Gil, W. Ahrens, K. Bammann, N. Michels, L.A. Moreno, et al., Analysis of the association of leptin and adiponectin concentrations with metabolic syndrome in children: results from the IDEFICS study, Nutr. Metab. Cardiovasc. Dis. 27 (June (6)) (2017) 543–551.

[16] J.F.B. Diamond, D. Cuthbertson, S. Hanna, D. Echler, Correlates of adiponectin and the Leptin/Adiponectin ratio in obese and non-obese children, J. Pediatr. Endocrinol. Metab. 17. January (8) (2004).

[17] J.P. Sutherland, B. McKinley, R.H. Eckel, The metabolic syndrome and inflammation, Metab. Syndr. Relat. Disord. 2 (2) (2004) 82–104.

[18] S. Devaraj, U. Singh, I. Jialal, Human C-reactive protein and the metabolic syndrome, Curr. Opin. Lipidol. 20 (June (3)) (2009) 182–189.

[19] J. Choi, L. Joseph, L. Pilotte, Obesity and Creative protein in various populations: a systematic review and meta-analysis: obesity and CRP in various populations J Chat et al, Obes. Rev. 14 (March (3)) (2013) 232–244.

[20] C.O. Mårtén, L.E. Melit, D.V. Ghio, M.O. Mårtén, Early inflammatory status related to pediatric obesity, Front. Pediatr. 7 (June (2019)) 241.

[21] K. Kitsios, M. Papadopoulos, K. Konta, N. Kadoglu, M. Papaniagia, K. Tsiroukidou, M. Christiansen, et al., Leptin, adiponectin, and their ratio as markers of insulin resistance and cardiometabolic risk in elderly with metabolic syndrome, Exp. Clin. Endocrinol. Diabetes 126 (July (07)) (2018) 445–452.

[22] D. Gradianu, D. Margina, C. Borsa, I. Ilie, M. Costache, et al., Adiponectin: possible link between metabolic stress and oxidative stress in the elderly, Aging Clin. Exp. Res. 29 (August (4)) (2017) 621–629.

[23] G. Moschonis, A. Kaliara, K. Karatzis, A. Michalatos, C.P. Lambrinou, A. Karachalioi, et al., Perinatal, sociodemographic and lifestyle correlates of increased total and visceral fat mass levels in schoolchildren in Greece: the Healthy Growth Study, Public Health Nutr. 20 (3) (March (13)) 44–49.

[24] D. Gradianu, H. Khaddour, D. Margina, A. Unguriana, C. Borsa, C. Ionescu, et al., Insulin-leptin Axis, cardiometabolic risk and oxidative stress in elderly with metabolic syndrome, Exp. Clin. Endocrinol. Diabetes 126 (July (07)) (2018) 445–452.

[25] D. Gradianu, D. Margina, C. Borsa, I. Ilie, M. Costache, et al., Adiponectin: possible link between metabolic stress and oxidative stress in the elderly, Aging Clin. Exp. Res. 29 (August (4)) (2017) 621–629.

[26] Y. Manios, K. Karatzis, A.D. Protogerou, G. Moschonis, C. Tsirimiagos, O. Andreouso, et al., Prevalence of childhood hypertension and hypertension phenotypes by weight status and waist circumference: the Healthy Growth Study, Eur. J. Nutr. 57 (April (3)) (2018) 1147–1155.

[27] J. Fernández, D. Redden, A. Pietrobelli, D. Allison, Waist circumference percentiles in nationally representative samples of African-American, European-American, and Mexican-American children and adolescents, J. Pediatr. 145 (4) (2004) 439–444.

[28] J.M. Tanner, Growth at Adolescence, 1955.

[29] M.A. El Assaad, J.A. Topouchian, R.G. Asmar, Evaluation of two devices for self-monitoring the levels of leptin, adiponectin and CRP levels in overweight and obese children in order to identify those with MetS, The Healthy Growth Study, Pediatrics 120 (August (2)) (2007) 340–345.

[30] J. Morrison, L. Friedman, P. Wang, C. Glaueck, Metabolic syndrome in childhood predicts adult metabolic syndrome and type 2 diabetes mellitus 25 to 30 years later, J. Pediatr. 152 (2) (2008) 201–206.
[36] American Academy of Pediatrics, National Cholesterol Education Program. Report of the expert panel on blood cholesterol levels in children and adolescents, Pediatrics 89 (1992) 525–584.

[37] P. Zimmet, G. Alberti, F. Kaufman, et al., The metabolic syndrome in children and adolescents - an IDF consensus report, Pediatr. Diabetes (2007) 299–306.

[38] A. Friend, L. Craig, S. Turner, The prevalence of metabolic syndrome in children: a systematic review of the literature, Metab. Syndr. Relat. Disord. 11 (April (2)) (2013) 71–80.

[39] C. Wittcopp, R. Conroy, Metabolic syndrome in children and adolescents, Pediatr. Rev. 37 (May (5)) (2016) 193–202.

[40] J.P. Halcox, C. Roy, F. Tubach, J.B. Banegas, J. Dallongeville, G. De Backer, et al., C-reactive protein levels in patients at cardiovascular risk: EURIK study, BMC Cardiovasc. Disord. 14 (December (1)) (2014) 25.